FDA approves Mylan overactive bladder drug
PITTSBURGH — The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.
Mylan announced the approval and launch of tolterodine tartrate tablets in the 1-mg and 2-mg strengths. The drug is a generic version of Detrol, made by Pharmacia and Upjohn, now owned by Pfizer.
Used to treat overactive bladder, tolterodine tartrate tablets had sales of about $61.5 million during the 12-month period ended in September, according to IMS Health.
NCPA releases progress report on medication adherence initiative
ALEXANDRIA, Va. — The National Community Pharmacists Association on Wednesday released Moving Forward on a Solid Foundation: Year One Progress Report, which examines the success of the association’s strategic initiative Pharmacists Advancing Medication Adherence.
The 16-page report covers July 2011 through July 2012 and outlines the tangible and measurable steps that are currently underway in facilitating the ability of independent community pharmacists to provide adherence services as a core competency of the profession, equivalent to the dispensing process, by 2015.
"NCPA is committed to advancing and improving patient medication adherence, which is why we launched this ambitious, comprehensive and realistic five-year program to address this problem," stated NCPA CEO Douglas Hoey. "As very accessible and highly trained medication experts that patients trust, independent community pharmacists are perfectly suited to help drive greater adherence. NCPA wants to help its members maximize their potential in this critical component of health care," he said. "We are confident that, when the five-year program concludes, the disturbing number of $290 billion a year being wasted on the improper use of medication will begin to recede and momentum for further improvement will be clear."
As part of PAMA, NCPA has launched Simplify My Meds, an adherence program that allows pharmacists to coordinate patients’ prescription refills on a single day of the month. This model facilitates a more comprehensive and coordinated level of pharmacy care, reduces the potential for gaps in therapy, and promotes improved medication adherence.
Research has confirmed that refill coordination at a single pharmacy is recognized as an effective tactic to improve adherence, and to date, more than 26,000 patients are benefiting from this service at more than 700 community pharmacies nationwide. NCPA also launched www.stick2thescript.org, an online resource that provides pharmacists and other healthcare providers with a comprehensive set of tools, programs and materials to use with patients to help them understand the goals and outcomes of their prescription regimen, manage their chronic conditions and take their medications as directed.
PAMA is supported by unrestricted grants from Cardinal Health Foundation, GlaxoSmithKline, Merck and Pfizer.
New York Gov. Cuomo visits PharmaSmart
NEW YORK — Kiosk manufacturer PharmaSmart got a visit from New York Gov. Andrew Cuomo Tuesday as he visited companies that his administration sees as leading the way in the state’s economic development.
PharmaSmart was one of two companies in the Rochester, N.Y., area and one of 20 in the state overall to become part of Cuomo’s Empire State Development Program.
PharmaSmart COO and general manager Ashton Maaraba said his company, which is preparing to move into a new, 50,000 sq. ft. manufacturing plant, was selected because it’s the initiator and developer of a product, and a company that does all its own manufacturing and distribution. "We’re a company that basically is leading the new wave of success stories throughout upstate New York," Maaraba told Drug Store News.
Maaraba touted the rising star of Rochester, also home to supermarket chain Wegman’s and a community-based healthcare system featuring a collaborative care model that works with local pharmacy retailers, which has seen a number of new companies crop up in the wake of the fall of photography giant Kodak. "Some of the most leading-edge health IT and biotechnology companies are being incubated, so you have an emerging ‘Silicon Valley’ emerging in Rochester," Maaraba said.